US 12180471
Antisense oligonucleotides for the treatment of Stargardt disease
granted A61KA61K31/713A61P
Quick answer
US patent 12180471 (Antisense oligonucleotides for the treatment of Stargardt disease) held by ProQR Therapeutics II B.V. expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ProQR Therapeutics II B.V.
- Grant date
- Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61K, A61K31/713, A61P, A61P27/02